MCIA Board

Chair Medicinal Cannabis Industry Australia

Peter Crock
CEO Cann Group

Peter Crock. Chair Medicinal Cannabis Industry Australia

Peter is an experienced public company senior manager with deep knowledge and expertise in marketing and technology development. Since joining Cann Group in May 2016, Peter has reset the business plan as directed by the board and led the company through a successful initial public offering (IPO) to list on the Australian Securities Exchange (ASX), raising $13.5 million while bringing outstanding institutional and cornerstone investor support. This was followed by a subsequent $70m+ capital raising within the same year to accelerate the company’s expansion program. In a 28-year career at Nufarm Limited (ASX: NUF), Peter held senior management roles in marketing, business development, and information technology and led Nufarm’s new technologies division which involved the licensing and commercial development of several new agribusiness technologies. He has project managed the successful integration of newly acquired businesses and has extensive experience working with regulators in Australia and overseas.


Rodney Cocks
CEO & Executive Director Cronos Australia

Rodney Cock. Director Medicinal Cannabis Industry Australia

Before founding Cronos Australia, Rodney was a consultant with The Boston Consulting Group, later taking up a senior role at an Australian multinational before co-founding NewSouthern Capital.  He heads up the capital raising and portfolio company teams at NewSouthern, and sits on the investment, audit and risk committee for the company.  As a graduate of the Royal Military College, Duntroon, Rodney commenced his career as an Australian Army infantry officer and was also a senior member of the UK Government’s Counter Narcotics team at The British Embassy in Kabul, which was responsible for targeting the massive opium and cannabis cultivation and trafficking issue in Afghanistan.  Rodney holds a Bachelor of Commerce, Bachelor of Laws, MBA (Wharton, University of Pennsylvania), and an MPA (Harvard University).  He is an admitted lawyer to the Supreme Court of New South Wales, a Graduate of the Australian Institute of Company Directors, and an Authorised Representative under an Australian Financial Services License.  Rodney was also named the Victorian Australian of the Year in 2005.

Ken Charteris
Group CEO  THC Global Group

Ken Charteris. Director Medicinal Cannabis Industry Australia

Ken is a veteran of multiple biotech and pharmaceutical companies over the past three decades as CEO, Managing Director and Chairman. In previous Executive roles Ken has had full P&L and balance sheet responsibility including legal and financial compliance in listed and international structures, leading businesses with revenue exceeding $200m and asset bases within $100m – $500m. Ken has a proven track record in hands on roles within major listed international companies improving profit growth and effecting share price increase.

Ken was involved in various senior levels within THC since prior to listing on the ASX, Ken has been instrumental in the execution of the Company’s strategic plan, including the acquisition of THC’s manufacturing facility and the securing of commercial partnerships with Ascent Industries (North America) and Endoca (Europe). Ken has a specific mandate to drive future acquisitions and alliances for THC.

Russell Harding
Executive Chairman & CEO MedReleaf Australia

Russell Harding. Director Medicinal Cannabis Industry Australia

Russell co-founded MedReleaf Australia with Nathan Davis in 2016 as a privately owned medicinal cannabis company. 

He has 35 years success in pharmacy business ownership, management and innovation combined with experience in a number of other fields including pharmacy wholesaling to an 80 member group of pharmacist proprietors, property development, business mentoring, medical centre management and semi-professional sports coaching as an accredited AFLQ senior coach.

Elisabetta Faenza MAICD
CEO LeafCann Group

Elisabetta Faenza. Director Medicinal Cannabis Industry Australia

Elisabetta is an expert in relationship management, optimising individual, organisational and societal outcomes, facilitating collaboration and fundraising through win-win relationships. As Co-Founder and CEO of LeafCann Group, Elisabetta has driven the organisation’s strategic positioning as an industry leader. With her core team Elisabetta has expertly laid the groundwork for product development, acquiring critical infrastructure, and developing patenting, licensing and certification pathways. This has positioned LeafCann as a future operational centre of excellence for the emergent Medicinal Cannabis sector in Australasia and Europe.

Elisabetta is a Clinical Hypnotherapist and consultant hypnotherapist to medical and allied health practices including; pain management specialists, physiotherapists, and dentists. Elisabetta has extensive experience as a strategic planner and relationship manager for transnationals and NGOs in the health and regenerative agriculture sectors. Her experience in project planning, strategic partnerships and fundraising has allowed her to identify key strategic partners and negotiate joint venture agreements both nationally and internationally.

Ido Kanyon
CEO AusCann

Ido Kanyon, MCIA Board member

Ido Kanyon is CEO of leading cannabinoid-based pharmaceutical company AusCann, and has extensive pharmaceutical and medical device business experience across the life-science value chain. This covers a comprehensive range of healthcare technologies and commercial strategies from capsules and inhalers to innovative biologics and digital health solutions. Mr. Kanyon has successfully launched innovative medicines globally, providing more patients with access to cost-effective, high-quality, life-changing treatment options.

Prior to AusCann, Mr. Kanyon held a broad range of executive positions at Teva Pharmaceuticals, a NYSE listed company with FY18 revenues of over US$18 billion. This included key leadership roles in Strategic Portfolio Management, Innovative Medicine Brand Marketing, Generics Pharmaceutical Manufacturing, Medical Device Regulatory Affairs and Quality Assurance.

Mr. Kanyon has also worked within an agricultural research organization, led R&D projects for start-up companies, and repeatedly transitioned academic research into robust class III implantable medical devices.
Mr. Kanyon holds a B.Sc. (Agr.) from The Hebrew University of Jerusalem, Israel, an MBA from IE Business School in Spain and Postgraduate training with McKinsey & Co. He holds a fellowship with the College of Physicians of Philadelphia and participates in advisory boards with several technological incubators, such as the leading US accelerator Dreamit Ventures. He has lived and worked in North America, Europe, Asia, and the Middle East.

Patty Holmes
bio available soon